3-(4,4-difluoropiperidin-1-yl)propan-1-amine | 869493-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(4,4-difluoropiperidin-1-yl)propan-1-amine
• CAS: 869493-53-8
• 化学式: C₈H₁₆F₂N₂
• 分子量: 178.225
• InChiKey: QFGAZHYAXWTEQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4,4-difluoropiperidin-1-yl)propan-1-amine 在 hydrazine hydrate 、 N,N-二异丙基乙胺 作用下， 以 乙二醇二甲醚 、 乙醇 为溶剂， 反应 50.0h， 生成 6-chloro-N-(3-(4,4-difluoropiperidin-1-yl)propyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine
  参考文献：
  名称：

  在乳腺癌模型中发现具有抗增殖活性的强效选择性 ATAD2 溴结构域抑制剂

  摘要：

  ATAD2 是一种表观遗传的含溴结构域的靶标，在许多癌症中过度表达，并已被建议作为潜在的肿瘤学靶标。虽然文献中已经描述了几种小分子抑制剂，但它们的细胞活性已被证明是平淡无奇的。在这项工作中，我们描述了通过高通量筛选鉴定一系列新的 ATAD2 抑制剂，确认溴域区域作为作用位点，以及为提高初始命中的效力、选择性和渗透性而进行的优化活动。结果是化合物5 (AZ13824374)，一种高效和选择性的 ATAD2 抑制剂，在一系列乳腺癌模型中显示出细胞靶标参与和抗增殖活性。

  DOI：

  10.1021/acs.jmedchem.1c01871

文献信息

• [EN] MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF<br/>[FR] COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'AGONISTES STING ET PROCÉDÉS ET UTILISATIONS DE CEUX-CI
  申请人：LUPIN LTD

  公开号：WO2021014365A1

  公开（公告）日：2021-01-28

  Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

  揭示了具有一般式（I）或（II）及其互变异构体、立体异构体、药学上可接受的盐、水合物、溶剂合物和前药的大环化合物，以及它们与适当药物的组合，本文披露的化合物的合成过程和药物组合物及其用途。
• Thienopyridinone compounds and methods of treatment
  申请人：Dhanoa S. Dale

  公开号：US20050256153A1

  公开（公告）日：2005-11-17

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻吩吡啶酮化合物，以及其合成和用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、促动力、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、心房颤动、缺血性中风、胃炎、胃排空障碍、进食障碍、消化道疾病、便秘、勃起功能障碍和呼吸抑制。还包括其制备方法、新颖中间体和药用盐。
• Synthesis of thienopyridinone compounds and related intermediates
  申请人：Dhanoa S. Dale

  公开号：US20060084805A1

  公开（公告）日：2006-04-20

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用途，用于治疗直接或间接通过5-HT受体介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• Thienopyridinone Compounds and Methods of Treatment
  申请人：Dhanoa Dale S.

  公开号：US20090163537A1

  公开（公告）日：2009-06-25

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用于治疗直接或间接由5-HT受体介导的疾病的用途。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF
  申请人：Lupin Limited

  公开号：EP4004002A1

  公开（公告）日：2022-06-01